Related Articles
Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss
Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis
Plasminogen activator inhibitor-1 in kidney pathology (Review)
Vascular cell-derived fibrinolytic regulators and atherothrombotic vascular disorders (Review).
Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review)